Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662942 · ClinicalTrials.gov registry record · Phase 1
StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms
A Phase 1 study of Vulvar Lichen Sclerosus, sponsored by Andrew T. Goldstein, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT06662942 is a Phase 1 study of Vulvar Lichen Sclerosus that is actively recruiting participants, run by Andrew T. Goldstein, MD. The registered enrollment target is 100 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06662942, a Phase 1 study of Vulvar Lichen Sclerosus, is actively recruiting participants, sponsored by Andrew T. Goldstein, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG StrataMGT
Study Locations (3)
District of Columbia
- Centers for Vulvovaginal Disorders, DC - Washington D.C.
Florida
- Centers for Vulvovaginal Disorders, FL - Tampa
New York
- Centers for Vulvovaginal Disorders, NY - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2025-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662942
The ClinicalTrials.gov registry entry for NCT06662942 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew T. Goldstein, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vulvar Lichen Sclerosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06662942 reports 3 study locations spanning 3 distinct geographic areas - top geographies include District of Columbia, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06662942 about?
NCT06662942 is a clinical study titled "StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms". This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.
What is the current status of trial NCT06662942?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-10-16. Estimated completion is 2025-10-16.
What conditions does trial NCT06662942 study?
This clinical trial studies the following conditions: Vulvar Lichen Sclerosus.
What interventions are being tested in trial NCT06662942?
The interventions under investigation include: Placebo (DRUG), StrataMGT (DRUG).
Who is sponsoring clinical trial NCT06662942?
This trial is sponsored by Andrew T. Goldstein, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06662942 being conducted?
This trial has 3 study locations across District of Columbia, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Lichen Sclerosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.